BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36095992)

  • 1. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.
    Akl L; Abd El-Hafeez AA; Ibrahim TM; Salem R; Marzouk HMM; El-Domany RA; Ghosh P; Eldehna WM; Abou-Seri SM
    Eur J Med Chem; 2022 Dec; 243():114704. PubMed ID: 36095992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
    Pecoraro C; Parrino B; Cascioferro S; Puerta A; Avan A; Peters GJ; Diana P; Giovannetti E; Carbone D
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 2-oxoindole derivatives as multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitors.
    Ezelarab HAA; Abd El-Hafeez AA; Ali TFS; Sayed AM; Hassan HA; Beshr EAM; Abbas SH
    Bioorg Chem; 2024 Apr; 145():107234. PubMed ID: 38412650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
    Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
    Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1.
    Carbone D; Pecoraro C; Panzeca G; Xu G; Roeten MSF; Cascioferro S; Giovannetti E; Diana P; Parrino B
    Mar Drugs; 2023 Jul; 21(7):. PubMed ID: 37504943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
    Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
    Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a promising hit from a new series of pyrazolo[1,5-a]pyrimidine based compounds as a potential anticancer agent with potent CDK1 inhibitory and pro-apoptotic properties through a multistep in vitro assessment.
    Elgiushy HR; Mohamed SH; Taha H; Sawaf H; Hassan Z; Abou-Taleb NA; El-Labbad EM; Hassan AS; Abouzid KAM; Hammad SF
    Bioorg Chem; 2022 Mar; 120():105646. PubMed ID: 35134645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Molecular Docking of Paracyclophanyl-Thiazole Hybrids as Novel CDK1 Inhibitors and Apoptosis Inducing Anti-Melanoma Agents.
    Aly AA; Bräse S; Hassan AA; Mohamed NK; El-Haleem LEA; Nieger M; Morsy NM; Alshammari MB; Ibrahim MAA; Abdelhafez EMN
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33260954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
    Said MA; Eldehna WM; Nocentini A; Fahim SH; Bonardi A; Elgazar AA; Kryštof V; Soliman DH; Abdel-Aziz HA; Gratteri P; Abou-Seri SM; Supuran CT
    Eur J Med Chem; 2020 Mar; 189():112019. PubMed ID: 31972394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
    Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
    Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with
    Abdelsalam EA; Abd El-Hafeez AA; Eldehna WM; El Hassab MA; Marzouk HMM; Elaasser MM; Abou Taleb NA; Amin KM; Abdel-Aziz HA; Ghosh P; Hammad SF
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2265-2282. PubMed ID: 36000167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.
    El-Shershaby MH; Ghiaty A; Bayoumi AH; Al-Karmalawy AA; Husseiny EM; El-Zoghbi MS; Abulkhair HS
    Bioorg Med Chem; 2021 Jul; 42():116266. PubMed ID: 34126285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
    Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
    Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.